Instil Bio, Inc. (TIL) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -37.17M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-37.17M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-55.03M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-78.58M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-80.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-89.45M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-80.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-73.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-74.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-117.83M | (m) | (m) | $20.65M | (m) | (m) |
| 2024-03-31 | $-124.68M | (m) | (m) | $26.19M | (m) | (m) |
| 2023-12-31 | $-159.17M | (m) | (m) | $39.60M | (m) | (m) |
| 2023-09-30 | $-202.95M | (m) | (m) | $58.34M | (m) | (m) |
| 2023-06-30 | $-192.88M | (m) | (m) | $89.51M | (m) | (m) |
| 2023-03-31 | $-230.62M | (m) | (m) | $122.55M | (m) | (m) |
| 2022-12-31 | $-226.46M | (m) | (m) | $141.06M | (m) | (m) |
| 2022-09-30 | $-223.41M | (m) | (m) | $162.91M | (m) | (m) |
| 2022-06-30 | $-209.79M | (m) | (m) | $152.31M | (m) | (m) |
| 2022-03-31 | $-186.44M | (m) | (m) | $132.00M | (m) | (m) |
| 2021-12-31 | $-155.56M | $0.00 | (m) | $107.25M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-33.64M | $138.00K | (m) | $19.40M | (m) | -24379.71% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |